A Phase II Study of Adjuvant Cisplatin and Gemsitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer

A Phase II Study of Adjuvant Cisplatin and Gemsitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer - A Phase II Study of Adjuvant Cisplatin and Gemsitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002855

Enrollment

Registered

2009-12-07

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A Phase II Study of Adjuvant Cisplatin and Gemcitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer

Interventions

Gemcitabine 1000mg/m2 Cisplatin 80mg/m2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically or cytologically confirmed diagnosis of non-small cell lung cancer. Completely resected with documented Stage II or Stage IIIA.

Exclusion criteria

Exclusion criteria: A recognized ILD or pulmonary fibrosis on X-rays.

Design outcomes

Primary

Measure	Time frame
1-year PFS	—

Secondary

Measure	Time frame
toxicity complete rate of treatment	—

Countries

Japan

Contacts

Public ContactAtsushi Horiike

Cancer Instiute Hospital Toracic Medical Oncology of Toracic Center

atsushi.horiike@jfcr.or.jp03-3520-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026